PATENT CLAIM ANALYSIS

Application Number: 16241839
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "253040"]

Abstract:
Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X 1 , X 2 , X 3  and X 4  have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

Claim (Index 12):
The method of  claim 1 , wherein the compound is BLU667 ((1s,4R)\u2014N\u2014((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)cyclohexane-1-carboxamide), or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 99.0
- Lexical Diversity: 1.63462
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15860852', '15860808', '15858240', '15860894', '15861244']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.80783617245478
- 35 USC 102 Novelty (BERT): 0.5827071156705246
- Combined Prediction Score: 0.7853232667763544
- Mean Citation Score: 467.299754
- Max Citation Score: 481.11722
- Similarity Product: 411.4747859433042

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test